Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$2.01
+$0.01 · +0.50%
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Previous close
$2.01
+$0.01 · +0.50%
After-hours
$1.9903
−$0.0197 · -0.98%
Oct 8, 5:07 PM ET
Regular session · ET · Market data may be delayed.
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Day range
Current $2.01
52-week range
Current $2.01
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
54
Mixed
Risk
62
High Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Day range
Current $2.01
52-week range
Current $2.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.02M USD | 1.76M USD | 1.3M USD | 69.96M USD | 2.57M USD |
| Cost of goods sold | — | — | — | 1.4M USD | 1.4M USD |
| Gross profit | 3.02M USD | 1.76M USD | 1.3M USD | 68.57M USD | 1.17M USD |
| Selling, general, and administrative | 6.85M USD | 6.1M USD | 8.9M USD | 56.71M USD | 80.75M USD |
| Operating expenses | 7.24M USD | 6.61M USD | 9.83M USD | 57.9M USD | 80.75M USD |
| Interest income | 150K USD | — | 300K USD | — | — |
| Interest expense | 8K USD | — | 200K USD | — | 32.92M USD |
| Depreciation and amortization | 1.19M USD | 509K USD | 922K USD | 1.2M USD | 736K USD |
| Operating income | −4.21M USD | −4.84M USD | −8.52M USD | 10.66M USD | −79.58M USD |
| Net income | −569K USD | −2.18M USD | −10.28M USD | 112M USD | −172.42M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 9, 2022 | 1:50 | — | — |
Stock split | Oct 3, 2011 | 1:100 | — | — |
Stock split | Jul 27, 2009 | 3:1 | — | — |
Effective May 9, 2022
1:50
Effective Oct 3, 2011
1:100
Effective Jul 27, 2009
3:1
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI532.61K0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF238.45K0.00%95.4B USD0.05%$233.13-0.15%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM30K0.03%116.54M USD0.73%$15.90-0.44%
U.S. Vector Equity Portfolio ETF Class SharesDXUV10.13K0.00%6.16B USD0.26%$68.11+0.22%
Dimensional - US Core Equity 2 ETFDFAC9.65K0.00%88.28B USD0.21%$45.11-0.15%
Dimensional - US Sustainability Core 1 ETFDFSU7.22K0.00%2.38B USD0.15%$47.88-0.08%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR6.15K0.00%45.43B USD0.17%$84.07-0.04%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
